
Eupraxia Pharmaceuticals
A company focused on the development of locally delivered, extended-release alternatives to currently approved drugs.
Market cap
$188m
Enterprise value
$200m
Share price
CAD7.14 EPRX.TO
Authorizing premium user...
A company focused on the development of locally delivered, extended-release alternatives to currently approved drugs.